Today: 30 April 2026
Browse Category

NASDAQ:MIST 12 December 2025 - 15 December 2025

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST (etripamil) nasal spray for adults with paroxysmal supraventricular tachycardia, marking the first new U.S. PSVT treatment in over 30 years. The company targets retail availability in Q1 2026. Shares showed sharp volatility after the announcement. Milestone scheduled an investor call for December 15 to discuss launch plans.
15 December 2025
·
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals said late Friday the FDA approved CARDAMYST (etripamil) as the first self-administered nasal spray for PSVT. MIST shares closed down 18.3% at $2.41 after volatile trading and heavy volume, but rebounded modestly after hours. CARDAMYST is expected in pharmacies in Q1 2026. In a Phase 3 trial, 64% of patients converted to normal rhythm within 30 minutes, compared to 31% on placebo.
14 December 2025
··
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST nasal spray for on-demand treatment of PSVT in adults, marking the first new U.S. therapy for the condition in over 30 years. The company expects CARDAMYST in pharmacies by Q1 2026. MIST shares were volatile ahead of the decision and ended the week lower despite the approval.
13 December 2025
··
Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals shares closed at $2.95 on Dec. 11, up 10.49% with about 7.54 million shares traded, ahead of an FDA decision on CARDAMYST nasal spray for PSVT due Dec. 13. The stock traded around $2.98 pre-market Dec. 12, rebounding from a 52-week low of $0.625 after an FDA rejection earlier in 2025 and subsequent resubmission.
12 December 2025
·

Stock Market Today

  • Sensex Falls Over 900 Points as Oil Prices Surge and Election Polls Trigger Volatility
    April 30, 2026, 12:31 AM EDT. Indian equity markets plunged on Thursday, with the Sensex dropping more than 900 points and the Nifty slipping below 23,900, driven by exit poll uncertainties for state elections and a sharp rise in Brent crude oil prices above $120 per barrel. The total market capitalization on the BSE fell by nearly Rs 6 lakh crore, signaling broad-based selling across large, mid, and small-cap stocks. Key sectors including Realty, Auto, Metals, and Banks all declined over 1%. Heightened geopolitical tensions, including U.S. threats of an extended blockade on Iranian ports, added to investor unease. Increased volatility, as measured by the India VIX, jumped about 5% to 18.29. Experts warn that sustained high oil prices may pressure India's economic growth and inflation outlook, possibly triggering further foreign portfolio outflows impacting market sentiment.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 30.04.2026

30 April 2026
OCBC will pay a total dividend of S$0.58 per share in May, including a S$0.16 special dividend. UOB declared a final dividend of S$0.71 per share despite lower net interest income. ST Engineering reported higher revenue and profit, with a S$0.23 per share dividend. Jardine Matheson raised its annual dividend 4% to US$2.35 per share, payable mid-May.
Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Go toTop